Trypanosoma cruzi, the protozoan agent of Chagas disease, has evolved an innovative metabolic pathway by which protective sialic acid (SA) residues are scavenged from host sialylglycoconjugates and transferred onto parasite surface mucin-like molecules (or surface glycoconjugates from host target cells) by means of a unique trans-sialidase (TS) enzyme. TS-induced changes in the glycoprotein sialylation profile of both parasite and host cells are crucial for the establishment of a persistent T. cruzi infection and for the development of Chagas disease-associated pathogenesis. In this chapter, we describe a novel metabolic labeling method developed in our labs that enables straightforward identification and molecular characterization of SA acceptors of the TS-catalyzed reaction.
Introduction
T. cruzi has evolved an innovative metabolic pathway by which the incorporation of sialic acid (SA) residues onto parasite molecules does not involve a conventional, Golgi-located cytidine monophosphate-SA:glycoconjugate sialyltransferase. Instead, SA residues are "scavenged" from host sialylglycoconjugates and transferred onto acceptor molecules on the parasite surface [1] . This reaction is catalyzed by a unique trans-sialidase (TS) enzyme and involves two steps: the cleavage of a terminal SA residue α2-3-linked to a ß-galactopyranose group in the donor macromolecule and the subsequent formation of an equivalent linkage in the acceptor substrate [2] [3] [4] [5] [6] [7] .
Acquisition of SA residues onto the parasite surface coat protects T. cruzi bloodstream trypomastigotes against the host immune system [8] and is crucial for their interaction with target cells [9] . In addition to its role in SA scavenging, TS emerges as a major T. cruzi phenotypic determinant, involved in multiple phenomena underlying parasite immune evasion, virulence, and pathogenesis. As shown, exposure to parasite-shed TS leads to modifications on the surface sialylation pattern of different host target cells such as platelets, T-and B-lymphocytes, and endothelial cells [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . This, in turn, changes the signaling/functional properties of these cells, allowing persistent T. cruzi infection and/or triggering Chagas disease-attributable symptoms [23] [24] [25] .
Functional dissection of T. cruzi biology has been restricted by the limited flexibility of the genetic manipulation technology applicable to this parasite [26] . Besides, the recognized structural and functional heterogeneity of the T. cruzi surface coat poses additional methodological complications for the identification of SA acceptors of the TS-mediated reaction [4, 27, 25] . As shown, SA acceptors on the parasite surface such as heavily O-glycosylated mucins and mucin-associated surface proteins (MASPs) are encoded by complex and developmentally regulated gene families showing differences in their polypeptide sequence and/or posttranslational processing, including O-glycosylation [28] [29] [30] [31] [32] . In this framework, metabolic labeling approaches emerge as particularly valuable tools for the identification and molecular characterization of SA acceptors of the TS-catalyzed reaction.
In the last years, novel metabolic labeling techniques that transcend the limitations of conventional strategies using radioactive or stable isotopes were developed. In these techniques, collectively known as Staudinger-Bertozzi ligation and click chemistry, the presence of the small chemical reporter used as a probe is revealed by a downstream chemical reaction with an exogenous label which is typically either a fluorophore or an affinity tag [33] . In the case of carbohydrate analogs, the most common modification is the presence of an azide group on the carbon 2, which does not interfere on their cellular uptake and/or subsequent incorporation into glycans [34] . Modified sugars are then labeled by different compounds capable of reacting with the azide group. Among azide-specific reactions, those involving phosphines and cyclooctynes (copperfree) are bio-inert and suitable to use in living cell, whereas those involving alkynes (copper-catalyzed) are very toxic and can be used to label fixed cells or cell extracts. Finally, the modularity of bioorthogonal chemical detection and ease of appending different labels to the azide-reacting compound (i.e., biotin group, affinity tag) allow multiple forms of glycoconjugate analysis (e.g., imaging and biochemical) or enrichment in a single experiment [34] .
In this chapter, we describe the protocol developed in our labs to study SA acceptors of the TS reaction on both T. cruzi parasites and different host cell types. This method is based on the use of a synthetic "SA donor" analog, i.e., a SA residue with an azide group on its carbon 9, which is α2-3-linked to a ß-galactopyranose. When added exogenously, such compound is recognized as a suitable SA donor by the T. cruzi TS, hence leading to the formation of a Neu5Azα2-3Galβ signature on SA acceptor glycoconjugates. Herein described method allowed the undertaking of structural and/or functional studies on the T. cruzi membrane composition and dynamics, and shed new light on the complex interphase between this parasite and the mammalian host [31, [35] [36] [37] [38] [39] . 10. Anti-FLAG M2 mAb magnetic beads or anti-DYKDDDDK affinity gel.
Materials
11. Magnetic separator.
12. Sterile Falcon and Eppendorf tubes and micropipette tips.
13. Refrigerated micro-centrifuge.
14. FLAG peptide.
Methods

Metabolic Labeling of Neosialylglycoconjugates Formed by T. cruzi trans-Sialidase
This protocol may be used to label T. cruzi parasites and different types of mammalian cells.
1. Wash the cell suspension three times with chill cold PBS (see Note 5).
2. Resuspend in PBS supplemented with 1 mM Neu5Azα2-3LacβOMe or 1 mM Neu5Azα2-3GalβOMe at 1 Â 10 3. Add 100 ng of recombinant T. cruzi TS (this step is not necessary when working with T. cruzi trypomastigotes) [2] (see Note 6). (Table 1) . 9. Immerse the coverslip three times (10 s each) in a 50 mLbeaker with PBS.
10. Incubate with secondary antibody in 100 μL of blocking solution for 1 h, in the dark.
11. Immerse the coverslip three times (10 s each) in a 50 mL beaker with PBS.
12. Incubate with DAPI (0.5 μg/mL in PBS) for 15 min.
13. Wash once with PBS.
14. Mount samples, and let dry overnight at RT, in the dark.
15. Observe slides under a fluoresce microscope (Fig. 1) . 3. Wash at least twice with PBS.
4. Incubate 1 Â 10 7 with 100 μL of PBS containing 25 mM NH 4 Cl for 30 min at RT (to quench surface aldehydes).
5. Wash once with PBS (1 mL), and block with 100 μL of IIF blocking buffer for 30-60 min.
6. Incubate with primary antibody in 100 μL of IIF blocking buffer for 1 h.
7. Wash three times with 1 mL of PBS.
8. Incubate with secondary antibody in 100 μL of blocking solution for 1 h, in the dark.
9. Wash three times with 1 mL of PBS.
10. Analyze using FACS (Fig. 2 ).
BiochemicalBased Methods
Western Blot
1. Label cells with the FLAG epitope or biotin as described in Subheading 3.1.
Resuspend parasites or mammalian cells in 1Â SDS-PAGE
sample buffer, and boil for 5 min.
3. Resolve extracts corresponding to 1.5 Â 10 7 cells into SDS-PAGE, and transfer onto PVDF or nitrocellulose membrane. low-fat dried milk or 2% BSA for Western blot development using anti-FLAG primary antibody or streptavidin-HRP, respectively.
5. Incubate for 1 h with anti-FLAG primary antibody or streptavidin-HRP (in case your sample is labeled with a biotin group) in blocking solution.
6. Wash three times with Western blot washing solution (10 min each).
7. Incubate with 2 μg/mL of secondary antibody in Western blot blocking solution.
8. Wash twice with Western blot washing solution (10 min each).
9. Wash once with TBS for 10 min. Avoid steps 7 and 8 when working with HRP-streptavidin.
10. Proceed with chemiluminescent detection.
Affinity Purification
1. Label cells with FLAG epitope as described in Subheading 3.1.
2. Lyse labeled cells or parasites with lysis/IP buffer for 15 min.
3. Centrifuge at 14,000 rpm for 30 min at 4 C.
4. Incubate the supernatant fraction for 16 h at 4 C with 100 μL of either anti-FLAG mAb magnetic beads or anti-DYKDDDDK affinity gel.
5. Wash four times with IP buffer (1 mL, 5 min each).
6. Elute with two column volumes of 1.5 mg/mL of FLAG peptide in IP buffer for 3 h or with 2Â SDS-PAGE sample buffer without reducing agents for 10 min (see Note 8).
Notes
1. Cultures of T. cruzi should be performed according to local regulations about biosafety and laboratory best practices, taking into consideration that parasites can be accidentally transmitted to humans through the mucosae or wounded skin. T. cruzi-infected animals and their organs should be manipulated as containing live parasites, thus possibly infective for humans. For details on how to obtain, culture, and purify major T. cruzi developmental forms (i.e., epimastigotes, metacyclic trypomastigotes, amastigotes, and cell-derived trypomastigotes), see [39] .
2. We are currently using an engineered TS molecule (accession number: L26499) bearing seven amino acid substitutions (Asn58Phe, Ser495Lys, Val496Gly, Glu520Lys, Asp593Gly, Ile597Asp, and His599Arg) as compared to the wild-type enzyme [2] .
3. We evaluated the performance of three bioorthogonal probes: phosphine-FLAG (Sigma, discontinued), dibenzylcyclooctyne-FLAG, and dibenzylcyclooctyne-biotin (both from Jena Bioscience). Their features and applications are detailed in Table 1. 4. We recommend either anti-FLAG M2 clone (Cat: F3165, Sigma) or anti-DYKDDDDK Tag Antibody clone L5 (Cat: 637303, Biolegend).
5. If you are working with adherent cells, avoid the use of proteolytic enzymes (like trypsin or collagenase) for cell de-attachment. In this case, we recommended the use of PBS supplemented with 2 mM EDTA and a cell scraper as de-attachment method.
6. When labeling mammalian cells or T. cruzi developmental forms that do not express a significant amount of TS (such as epimastigotes) it is required the addition of recombinant T. cruzi TS. In the presence of T. cruzi TS, lack of labeling may be attributed to steric hindrance phenomena or, more likely, to the absence of SA acceptors (i.e. glycoconjugates bearing terminal ß-galactopyranoses in the correct configuration) on the surface of the target cell. In this regard, it is noteworthy that T. cruzi amastigote forms, in spite of expressing certain mucin-like genes [40] are completely refractory to TS-catalyzed sialylation (see Fig. 2 ).
7. This incubation step may also be performed on ice, with a concomitant decrease in labeling efficiency [39] .
8. Avoid the use of low pH solutions (i.e. 0.1 M Glycine HCl, pH 3.0) for elution because the SA linkage is labile under these conditions.
